Clinical trial

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

NCT03926091

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-04-01

PhasePHASE3

Study timeline

Study start (actual)2019-04-01Date precision: day

Registry last updated2023-11-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China2 HangzhouZhejiang, China2 GuangzhouGuangdong, China1 TianjinTianjin Municipality, China1 ChangchunJilin, China1 ShenyangLiaoning, China1 ChongqingChongqing Municipality, China1 FuzhouFujian, China1 HarbinHeilongjiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03926091 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.